Clinically Validated Probiotics
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Two Acts, One Geopolitical Moment
Beyond Reporting - Safety surveillance analytics for medical devices...
Elevating Drug Safety
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Takeda Pharmaceutical Company Limited
Chief Medical & Scientific Officer
Scientific progress depends upon collaboration iPS cell technology is at the forefront of pharmaceutical innovation and Takeda strives to bring innovative treatments to patients Both Takeda and CiRA have the common goal of providing patients and healthcare professionals with innovative new treatments
Articles
Alpha-fetoprotein as a Shuttle for Medicines
Pregnancy is a natural phenomenon that ensures the survival of the species The suppression of the immune response in pregnancy is robust since the embryo cells have half the fathers proteins that should be recognised by the mothers immune system as foreign Even surrogate motherhood is possible with no genetic relationship to the embryo at all The embryo cell is turning
Research Insights
Radiation Necrosis after Radiation Therapy Treatment of Brain Metastases: A Computational Approach
Brain metastases are the most common intracranial malignancies in adults with around of patients with cancer developing brain metastases during the course of their diseases Most BMs originate from primary cancers from lung
Case Studies
Analytics Stories: A Case Study from Quintiles
As I have shared within other posts within this series businesses are using analytics to improve their internal and external facing business processes and to strengthen their right to win within the markets that they operate For pharmaceutical businesses strengthening the right to win begins and ends with the drug product development lifecycle I remember for example t...
Techno Trends
GSK Introduces a New Anti-BCMA (B-cell maturation antigen) Therapy, BLENREP
GlaxoSmithKline plc introduces BLENREP a firstinclass antiBCMA Bcell maturation antigen therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an antiCD monoclonal antibody
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Current Challenges in Fully Digitising Manufacturing for Biotech and Cell and Gene Therapy Companies
Abhijit has led teams for large enterprises helping them take their performance to the cloud. He has implemented AI/ML solutions, IoT frameworks, and cloud infrastructure.
Impact Assessment of US Tariff Threat on Indian Healthcare Export
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
CAR-T Cell Therapy and NexCAR19
Dr Ashwini Kumar is presently working as an Assistant Professor in the Biotechnology and Bioinformatics Area at NIIT University, Neemrana (Rajasthan), India. Biomaterial science has been the main focus of Ashwini's research, particularly in the area of cutting-edge drug delivery techniques. His research's intended uses are developing minimally invasive and non-invasive medication delivery strategies to improve patient compliance and outcomes. Two other area that pique his curiosity are tissue engineering and diabetes. Ashwini is the author for twenty-two journal articles published in both domestic and foreign journals, eight book chapters, a book. In addition, he has a patent for his PhD work. He has been asked to participate in juries and speak on several national scientific venues. He has been working as a reviewer for reputable journals published by Frontiers, Elsevier, and Wiley. He is a guest editor of Frontiers in Medical Technology, a focused journal from Frontiers Publications, and a regular reviewer of Materials and Design, Elsevier. He is a life member of Asian Polymer Association.
press releasesRead more...
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery
Rakovina Therapeutics Inc TSXV RKV FSE JO OTCMKTS RKVTF a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery today announced
Roche opens up new possibilities for genomic research in Asia Pacific with next-generation sequencing technology
Roche is advancing its nextgeneration sequencing NGS ambitions in Asia Pacific following the global launch of AXELIOS in June Building on early adoption in South Korea Roche will bring the transformative technology closer to researchers and laboratory leaders across the region through AXELIOS Days
Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses
Charles River Laboratories International Inc announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporations bioanalysis and DMPK operations in Exton Pennsylvania for approximately million in cash subject to customary closing adjustments In addition to the i...
Sino Biological Advances AI-Designed Molecule Validation with 4RISE™
AI can generate protein candidates at an unprecedented speed but experimental validation remains essential to determine whether they properly express bind targets and demonstrate the desired biological properties Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in recombinant protein t...
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
LATEST NEWSRead more...
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention
Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
